Cited by 223Nicotinic Acetylcholine Receptors StudySmoking Behavior and CessationSubstance Abuse Treatment and Outcomes

Human Tobacco Smokers in Early Abstinence Have Higher Levels of β2* Nicotinic Acetylcholine Receptors than Nonsmokers

Open access
Staley, Julie K., Krishnan-Sarin, Suchitra, Cosgrove, Kelly P., Krantzler, Erica, Frohlich, Erin, Perry, Edward, Dubin, Joel A., Estok, Kristina +9 more·2006·The Journal of Neuroscience

Abstract

Nicotine, the addictive chemical in tobacco smoke, initiates its actions in brain through nicotinic acetylcholine receptors (nAChRs). In particular, nAChRs containing β 2-subunits (β 2*-nAChRs) the most prevalent subtype, mediate the reinforcing properties of nicotine. We hypothesized that abnormal numbers of β 2*-nAChRs during early abstinence contribute to the perpetuation of addiction to tobacco smoking. Using molecular imaging, specifically single-photon emission computed tomography with the nAChR agonist radiotracer [123 I]5-IA-85380 ([123 I]5-IA), we imaged β 2*-nAChR availability in human smokers. First, using nonhuman primates treated chronically with nicotine, we estimated the time interval necessary for smokers to abstain from smoking so that residual nicotine would not interfere with [123 I]5-IA binding to the β 2*-nAChR as ∼7 d. Thus, we imaged human smokers at 6.8 ± 1.9 d (mean ± SD) of abstinence. Abstinence was confirmed by daily assessments of urinary cotinine and expired carbon monoxide levels. In smokers, [123 I]5-IA uptake was significantly higher throughout the cerebral cortex (26–36%) and in the striatum (27%) than in nonsmokers, suggesting higher β 2*-nAChR in recently abstinent smokers. β 2*-nAChR availability in recently abstinent smokers correlated with the days since last cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or the desire to smoke. Higher brain β 2*-nAChR during early abstinence indicates that, when smokers quit smoking, they do so in the face of a significant increase in the receptors normally activated by nicotine. Greater β 2*-nAChR availability during early abstinence may impact the ability of smokers to maintain abstinence.

AI snapshot

Written from the paper’s full text.

TL;DR

Using [123I]5-IA SPECT, this study found that human smokers in early abstinence have higher brain β2*-nicotinic acetylcholine receptor availability than nonsmokers. The authors suggest this upregulation may influence the ability to maintain smoking abstinence.

Key findings

  • Smokers imaged after 6.8 ± 1.9 d of abstinence showed significantly higher [123I]5-IA uptake than nonsmokers throughout cerebral cortex (26–36%) and in striatum (27%); region-of-interest analyses also showed higher uptake in cerebellum (25.2%) but not thalamus (8.7%, p = 0.1651).
  • In nonhuman primates, [123I]5-IA binding decreased 41–65% after 1–2 d of nicotine withdrawal, then increased 240–276% after 7 d of withdrawal, supporting an approximately 7 d abstinence interval before human imaging.
  • In smokers, β2*-nAChR availability correlated with days since last cigarette and with urge to smoke to relieve withdrawal symptoms, but not with severity of nicotine dependence, severity of nicotine withdrawal, or desire to smoke.

Methods

  • Two male adolescent rhesus macaques received oral nicotine dose escalation and were imaged with [123I]5-IA SPECT at baseline, after 6 weeks of nicotine plus 1–2 d withdrawal, and after 8 weeks of nicotine plus 7 d withdrawal.
  • Human smokers (n = 16) and nonsmokers (n = 16) matched on age and sex were imaged with [123I]5-IA SPECT using a bolus-plus-constant-infusion paradigm; smokers abstained for 6.8 ± 1.9 d, confirmed by urinary cotinine and expired carbon monoxide.
  • Regional β2*-nAChR availability was measured as V_T′ using MRI-guided regions of interest and voxel-based SPM2 analyses; group differences used MANOVA and t tests, and clinical correlations used Pearson’s correlation.

Limitations

  • The paper states that a species difference cannot be ruled out because nonhuman primates were male adolescents while human smokers were male and female adults, and it notes that interindividual variability in nicotine metabolism/CYP2A6 is expected.
  • The paper reports that technical problems precluded determining plasma levels in one monkey at 6 weeks/2 d withdrawal.
  • Evident from the text: human samples were small (n = 16 per group), cross-sectional, and correlational; V_T′ interpretation assumes no change in affinity and no difference in nondisplaceable uptake.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1523/jneurosci.0546-06.2006

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

5 of 36 cited sources checked · 1 supported · 0 flagged · accuracy not yet measured

  • Premisecitation

    Nicotine competes with [123I]5-IA binding for binding to nAChRs.

    “Because nicotine competes with [ 123 I]5-IA binding for binding to nAChRs (Mukhin et al., 2000)”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Mukhin et al., 2000 source

      The available indexed passages (no section or page labels) list nicotine and 5-iodo-A-85380 as receptor ligands, but do not describe nicotine competing with [123I]5-IA for binding. Searches for nicotine displacement, inhibition, and competitive binding returned no passage addressing that relationship. (LLM, conf=0.70)

      Experimental — accuracy not yet measured
  • Premisecitation

    [123I]5-IA is a radioligand that has specificity for the agonist binding site on β2*-nAChRs.

    “With the recent development of [ 123 I]5-IA-85380 ([ 123 I]5-IA), a radioligand that has specificity for the agonist binding site on ␤ 2 *- nAChRs (Musachio et al., 1998(Musachio et al., , 1999;;Horti et al., 1999)”
    Quote in the paperSubstantial claim2 of 3 sources checked
    • cites Musachio et al., 1998 source

      The Results (page not provided) show that nAChR agonists inhibited [125I]5-IA binding in mouse brain, and the Discussion reports specificity for central nAChRs. However, the Discussion only predicts selectivity for the α4β2 subtype; it does not establish specificity for the agonist binding site on β2*-nAChRs. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites Musachio et al., 1999 source

      The Discussion (page not provided) describes [123I]5-IA as a highly specific probe for central nAChRs and reports that the agonist cytisine blocked its uptake in baboon brain. It does not establish specificity for the agonist binding site on β2*-nAChRs; it says only that radioiodinated 5-IA might be more selective for the α4β2 subtype. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites Horti et al., 1999 source
  • Premisecitation

    Greater β2*-nAChR availability appears attributable to occupancy of the nicotine binding site that bridges the α/β subunit interface in an immature, low-affinity conformation that facilitates glycosylation and maturation of the α4β2 nAChR to a more stable conformation with higher affinity for nicotine.

    “but instead appears to be attributable to occupancy of the nicotine binding site that bridges the ␣/␤ subunit interface of the nAChR in an immature, low-affinity conformation that facilitates glycosylation and maturation of the ␣ 4 ␤ 2 nAChR to a more stable conformation with higher affinity for nicotine (Darsow et al., 2005;Sallette et al., 2005).”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites Darsow et al., 2005 source
    • cites Sallette et al., 2005 source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
  • Findingown data

    β2*-nAChR availability in recently abstinent smokers correlated with the urge to smoke to relieve withdrawal symptoms.

    “␤ 2 *-nAChR availability in recently abstinent smokers correlated with the days since last cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or the desire to smoke.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
    • Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
  • Findingown data

    In recently abstinent smokers, [123I]5-IA uptake was significantly higher throughout the cerebral cortex (26-36%) and in the striatum (27%) than in nonsmokers.

    “In smokers, [ 123 I]5-IA uptake was significantly higher throughout the cerebral cortex (26 -36%) and in the striatum (27%) than in nonsmokers, suggesting higher ␤ 2 *-nAChR in recently abstinent smokers.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
    • Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
  • May combine two claims. 14
  • Classified as probably not a substantial claim. 13
  • May combine two claims.

    Premisecitation

    Greater β2*-nAChR availability is not associated with changes in β2*-nAChR mRNA, protein synthesis, rate of receptor internalization, postendocytic trafficking, or lysosomal degradation.

    “Greater ␤ 2 *- nAChR availability is not associated with changes in ␤ 2 *-nAChR mRNA (Marks et al., 1992;Peng et al., 1994;Zhang et al., 1994) protein synthesis (Buisson and Bertrand, 2001), rate of receptor internalization, postendocytic trafficking, or lysosomal degradation (Darsow et al., 2005)”
    Quote in the paperSubstantial claim1 of 3 sources checked
    • cites Marks et al., 1992 source
    • cites Peng et al., 1994 source
    • cites Zhang et al., 1994 source
  • May combine two claims.

    Findingown data

    The concentration of unmetabolized [123I]5-IA and the percentage of [123I]5-IA not bound to plasma proteins did not vary significantly between nonsmokers and smokers.

    “The concentration of unmetabolized [ 123 I]5-IA and the percentage of [ 123 I]5-IA not bound to plasma proteins ( f 1 ) did not vary significantly between nonsmokers and smokers [0.31 Ϯ 0.09 and 0.26 Ϯ 0.08 kBq/ml, respectively; 95% confidence interval (Ϫ0.114, 0.009); p ϭ 0.09; and 35.4 Ϯ 3.2 and 36.6 Ϯ 4.9%, respectively; p ϭ 0.44].”
    Quote in the paperSubstantial claim
    • Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
  • May combine two claims.

    Findingown data

    There were no significant correlations between regional β2*-nAChR availability and number of cigarettes smoked per day, severity of nicotine dependence, severity of nicotine withdrawal, or the urge to smoke (general) in either region-of-interest or voxel-based analyses.

    “There were no significant correlations between regional ␤ 2 *-nAChR availability and number of cigarettes smoked per day, severity of nicotine dependence, severity of nicotine withdrawal, or the urge to smoke for either region of interest analyses or voxel-based analyses.”
    • Also stated in: § Discussion · plain
      “We did not observe a relationship between ␤ 2 *-nAChR avail- ability in brain and the number of cigarettes smoked per day”
    • Also stated in: § Discussion · plain
      “there was no evidence for a significant correlation between ␤ 2 *-nAChR avail- ability and the severity of nicotine withdrawal assessed by the MWS on the scan day.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
  • May combine two claims.

    Findingown data

    β2*-nAChR availability (VT') is higher in recently abstinent smokers than nonsmokers in the striatum, cerebellum, and cerebral cortex (parietal, frontal, anterior cingulate, temporal, and occipital cortices), but not in the thalamus.

    “This report provides the first direct evidence that brain ␤ 2 *-nAChR densities are higher in the striatum, cerebellum, and cerebral cortex during early abstinence in living human smokers compared with nonsmokers”
    • Also stated in: § Discussion · plain
      “striatal, cortical, and cerebellar [ 123 I]5-IA uptake values were significantly higher in the smokers compared with the nonsmokers ( p values ϭ 0.0002, 0.0001, and 0.0013, respectively), whereas there was no significant difference in thalamic [ 123 I]5-IA uptake.”
    • Also stated in: § Discussion · plain
      “recently abstinent smokers have more cortical, striatal, and cerebellar ␤ 2 *-nAChR sites available for binding than nonsmok- ers”
    Quote in the paperSubstantial claim
    • Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
  • May combine two claims.

    Findingown data

    In smokers, β2*-nAChR availability was higher throughout the cerebral cortex, striatum, and cerebellum but not thalamus, whereas nicotine-treated nonhuman primates exhibited higher [123I]5-IA binding throughout all brain regions.

    “There were notable regional differences in ␤ 2 *-nAChR avail- ability in smokers with robustly higher levels throughout the cerebral cortex, striatum, and cerebellum but not thalamus compared with the nicotine-treated nonhuman primates, which exhibited higher [ 123 I]5-IA binding throughout all brain regions.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.
    • Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
  • May combine two claims.

    Findingown data

    In nonhuman primates, after 6 weeks of oral nicotine, 1-2 days of withdrawal caused a 41-65% decrease in [123I]5-IA uptake, and after 8 weeks, 7 days of withdrawal caused a >200% increase.

    “Note the reproducibility of measurement indicated by lack of change between B1 and B2, the profound decrease followed by 1-2 d of withdrawal (41-65% change at 6 weeks of nicotine treatment), and the dramatic increase followed by 7 d of withdrawal (Ͼ200% after 8 weeks of nicotine treatment).”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    Self-reports of menstrual cycle phase were validated by plasma estrogen and progesterone levels.

    “Self-reports of menstrual cycle phase were validated by plasma estrogen and progesterone levels.”
    Quote in the paperNot a substantial claim
  • Classified as probably not a substantial claim.

    Study design and conductcitation

    Regional β2*-nAChR availability was determined by V_T' (regional activity/total plasma parent), a highly reproducible outcome measure.

    “Regional ␤ 2 *-nAChR availability was determined by V T Ј (regional activity/total plasma parent), a highly reproducible outcome measure (Staley et al., 2005).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Staley et al., 2005
    • Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationreasoning

    The ability of nicotine to regulate β2*-nAChR availability may be age or sex dependent, because the nonhuman primates were male adolescents and the smokers were male and female adults.

    “Although a species difference cannot be ruled out, this divergence may suggest that the ability of nicotine to regulate ␤ 2 *-nAChR availability is age or sex dependent because the nonhuman primates were male adolescents and the smokers were male and female adults (Slotkin, 2002;Nguyen et al., 2003).”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites Slotkin, 2002 source
    • cites Nguyen et al., 2003 source
    • Rests on an assumption: The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.
  • Classified as probably not a substantial claim.

    Premisecitation

    Animals exposed to nicotine chronically exhibit increased levels of nAChRs in the brain.

    “animals exposed to nicotine chronically exhibit increased levels of nAChRs in the brain (Marks et al., 1983(Marks et al., , 1985(Marks et al., , 1992;;Schwartz and Kellar, 1983)”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Marks et al., 1983 source
    • cites Marks et al., 1985 source
    • cites Schwartz and Kellar, 1983 source
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductcitation

    Inter-rater reliability for V_T' across eight brain regions ranged between 0.82 and 0.97.

    “The interclass coefficient to assess inter-rater reliability (Rousson et al., 2002) ranged between 0.82 and 0.97 for the V T Ј measure across the eight brain regions.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Rousson et al., 2002 source
    • Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
  • Classified as probably not a substantial claim.

    Study design and conductnone given

    Abstinence was confirmed by daily assessments of urinary cotinine and expired carbon monoxide levels.

    “Abstinence was confirmed by daily assessments of urinary cotinine and expired carbon monoxide levels.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
  • Classified as probably not a substantial claim.

    Premisecitation

    Postmortem studies of human brain have suggested that numbers of nAChRs are higher in smokers than in nonsmokers or former smokers.

    “Postmortem studies of human brain have suggested that numbers of nAChRs are higher in smokers than in nonsmokers or former smokers (Benwell et al., 1988;Breese et al., 1997;Perry et al., 1999)”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Benwell et al., 1988 source
    • cites Breese et al., 1997 source
    • cites Perry et al., 1999 source
  • May combine two claims.

    Study design and conductown data

    On the SPECT scan day, urinary cotinine levels were <250 ng/ml for 14 of 16 smokers and <1000 ng/ml for two smokers.

    “On the SPECT scan day, urinary cotinine levels were Ͻ250 ng/ml for 14 of 16 smokers and Ͻ1000 ng/ml for two smokers.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationcitation

    The relationship between greater β2*-nAChR availability and nAChR function may vary in a region-dependent manner attributable to different subunit combinations that demonstrate increased agonist binding but differ in effects on function.

    “The relationship between greater ␤ 2 *-nAChR availability and nAChR function may vary in a region-dependent manner attributable to different subunit combinations that demonstrate increased agonist binding but differ in the effects on function (Rush et al., 2002).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Rush et al., 2002 source
  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Craving (the urge to smoke) is a prominent feature of nicotine dependence and is a primary factor associated with relapse.

    “Although most withdrawal symptoms resolve after a few days of abstinence, craving (i.e., the urge to smoke) is a prominent feature of nicotine dependence (Tiffany and Drobes, 1991) and is a primary factor associated with relapse (Killen et al., 1997).”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites Tiffany and Drobes, 1991 source
    • cites Killen et al., 1997

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Interpretationcitation

    The rapid pharmacokinetics of nicotine were observed after a single administration of a trace dose of intravenous nicotine, and accumulation of nicotine and/or metabolites in brain may differ with protracted and repeated nicotine administration.

    “The rapid pharmacokinetics were observed, however, after a single administration of a trace dose of intravenous nicotine, and the accumulation of nicotine and/or metabolites (Vainio and Tuominen, 2001) in brain may differ with protracted and repeated nicotine administration.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Vainio and Tuominen, 2001 source
  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

    Premisenone given

    Urinary cotinine, the primary metabolite of nicotine, has a longer half-life than nicotine and appears to be a useful indicator of the clearance of nicotine or a metabolite from brain.

    “Urinary cotinine, the primary metabolite of nicotine, has a longer half-life than nicotine and appears to be a useful indicator of the clearance of nicotine or a metabolite from brain.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).

    Interpretationreasoning

    The severity of nicotine withdrawal is likely determined by the complex interplay between β2*-nAChRs and other neurochemical systems.

    “Because of the myriad of symptoms and the wide-ranging actions of nicotine on brain neurochemistry, the severity of nicotine withdrawal is likely determined by the complex interplay between ␤ 2 *-nAChRs and other neurochemi- cal systems.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
  • May combine two claims.

    Premisecitation

    Nicotine is highly lipophilic and, when radiolabeled, demonstrates very high levels of nonspecific brain uptake.

    “Nicotine is highly lipophilic and, when radiolabeled, demonstrates very high levels of nonspecific brain uptake (Broussolle et al., 1989;Muzic et al., 1998).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites Broussolle et al., 1989 source
    • cites Muzic et al., 1998
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Interindividual variability in nicotine metabolism in human smokers is expected because individuals with different CYP2A6 genotypes differentially metabolize nicotine.

    “Interindividual variability in nicotine metabolism in human smokers is expected because individuals with different CYP2A6 genotypes differentially metabolize nicotine (Tyndale and Sellers, 2001).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Tyndale and Sellers, 2001
  • May combine two claims.

    Premisecitation

    The α4β2 combination is the most prevalent β2*-nAChR combination and the most sensitive to upregulation by nicotine.

    “Although ␤ 2 subunits exist in several different combi- nations with ␣ 2 , ␣ 3 , ␣ 4 , and ␣ 6 subunits, the ␣ 4 ␤ 2 combination is most prevalent and also the most sensitive to upregulation by nicotine (Nguyen et al., 2003;Sallette et al., 2004).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites Nguyen et al., 2003 source
    • cites Sallette et al., 2004 source
  • May combine two claims.

    Premisenone given

    Large individual differences in urinary cotinine clearance have been observed in human smokers over the first week of abstinence, with cotinine levels declining to levels comparable with those in nonsmokers over a 4-7 day period after smoking cessation.

    “Importantly, large individual differences in urinary cotinine clearance have been observed in human smokers over the first week of abstinence, with cotinine levels declining to levels comparable with those in nonsmokers over a 4 -7 d period after smoking cessation.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Premisecitation

    The terminal half-life of nicotine is 1.6 h in macaques, and radiolabeled nicotine rapidly clears from brain.

    “The apparent long residence time of nicotine on ␤ 2 *-nAChR in brain is sur- prising given that the terminal half-life of nicotine is 1.6 h in macaques (Schoedel et al., 2003) and that radiolabeled nicotine rapidly clears from brain (Crooks and Dwoskin, 1997;Crooks et al., 1997).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Schoedel et al., 2003 source
    • cites Crooks and Dwoskin, 1997

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites Crooks et al., 1997

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

24 of 24
  • The paper relies on this without support.

    Nicotine initiates its actions in the brain through nicotinic acetylcholine receptors (nAChRs).

    “Nicotine, the addictive chemical in tobacco smoke, initiates its actions in brain through nicotinic acetylcholine receptors (nAChRs).”
  • The paper relies on this without support.

    The addictive properties of tobacco smoke are attributed primarily to nicotine.

    “Although tobacco smoke contains Ͼ4000 chemicals, its addictive properties have been attributed primarily to nicotine.”
  • The authors state this as an assumption.

    V_T' is proportional to binding potential (Bmax/KD), assuming no change in affinity (KD) and that nondisplaceable uptake does not differ between animals and studies.

    “The primary outcome measure for regional brain uptake was V T Ј, which is proportional to the binding potential (BP) (B max /K D ), assuming that there is no change in affinity (K D ) and that nondisplaceable uptake does not differ between animals and studies.”
  • The paper relies on this without support.

    The time course of nicotine clearance and receptor availability in nonhuman primates is similar enough to humans to determine the necessary abstinence interval for human smokers.

    “First, using nonhuman primates treated chronically with nicotine, we estimated the time interval necessary for smokers to abstain from smoking so that residual nicotine would not interfere with [ 123 I]5-IA binding to the ␤ 2 *-nAChR as ϳ7 d.”
  • The paper relies on this without support.

    V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.

    “Regional ␤ 2 *-nAChR availability was determined by V T Ј (regional activity/total plasma parent), a highly reproducible outcome measure (Staley et al., 2005).”
  • The paper relies on this without support.

    Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.

    “On the SPECT scan day, urinary cotinine levels were Ͻ250 ng/ml for 14 of 16 smokers and Ͻ1000 ng/ml for two smokers.”
  • The paper relies on this without support.

    The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.

    “These findings were substantiated by our experiment in nonhuman primates that confirmed that higher ␤ 2 *-nAChR availability is at- tributable to nicotine (vs other chemicals in tobacco smoke)”
  • The paper relies on this without support.

    The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.

    “Higher brain [ 123 I]5-IA uptake in recently abstinent smokers suggests greater availability of nicotine binding sites on ␤ 2 *- nAChRs.”
8 of 8

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Our data extend the findings of previous studies which showed that the upregulation of the β2*-nAChR in recently abstinent tobacco smokers was temporary and could be measured with [123I]5-IA SPECT imaging.

    “In summary, our data extend the findings of previous studies8, 18 which showed that the upregulation of the β2*-nAChR in recently abstinent tobacco smokers was temporary and could be measured with [123I]5-IA SPECT imaging.”

    From β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco Smoking (2009) · cites this paper as [8]

    The Results report higher β2*-nAChR availability in recently abstinent smokers than in nonsmokers, measured with [123I]5-IA SPECT. The study does not establish that this upregulation was temporary in human smokers; it imaged them during early abstinence rather than following receptor levels over time. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Chronic smokers have more cortical, striatal, and cerebellar β2* nAChRs than non-smokers.

    “it was found that chronic smokers have more cortical, striatal, and cerebellar β2* nAChRs than non-smokers (Staley et al. 2006).”

    From Nicotine Withdrawal (2015) · cites this paper as Staley et al. 2006

    The Discussion reports higher β2*-nAChR densities in the cortex, striatum, and cerebellum of smokers than nonsmokers, and Table 2 shows higher availability in those regions. The smokers were studied during early abstinence; the claim omits that condition and therefore implies a broader finding about chronic smokers. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • β2*-nAChR availability is higher in recently abstinent smokers compared to never smokers.

    “β2*-nicotinic acetylcholine receptor (β2*-nAChR) availability is higher in recently abstinent smokers compared to never smokers.”
  • The difference between recently abstinent smokers and never smokers in the previous study was of greater magnitude (26-36% in cerebral cortex and 27% in striatum) than in the current study (21-29% in cerebral cortex and 22% in striatum).

    “The difference between recently abstinent smokers and never smokers in the previous study8 was of a greater magnitude, e.g., 26-36% in the cerebral cortex and 27% in the striatum, than in the current study, e.g., 21-29% in the cerebral cortex and 22% in the striatum.”
  • A previous study found a negative correlation between the urge to smoke to relieve withdrawal symptoms and β2*-nAChR availability in the sensorimotor cortex at approximately 1 week of abstinence.

    “We previously found a negative correlation between the urge to smoke to relieve withdrawal symptoms and β2*-nAChR availability in the sensorimotor cortex at approximately 1 week of abstinence8.”

Cites

Flagged first, then by citations

7 of the 64 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Staley, J. K., Krishnan-Sarin, S., Cosgrove, K. P., Krantzler, E., Frohlich, E., Perry, E., Dubin, J. A., Estok, K., Brenner, E., Baldwin, R. M., Tamagnan, G. D., Seibyl, J. P., Jatlow, P., Picciotto, M. R., London, E. D., O'Malley, S., & van Dyck, C. H.
Affiliations
  • Yale University (US)
  • VA Connecticut Healthcare System (US)
  • Institute for Neurodegenerative Disorders (US)
  • University of California, Los Angeles (US)
Corresponding author
Staley, Julie K.
Venue
The Journal of Neuroscience
Published
2006-08-23
Volume
26
Issue
34
Pages
8707-8714
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2165081822
Cited by
223
References
64
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 4 · 2021: 4 · 2020: 26 · 2019: 5 · 2018: 16 · 2017: 8 · 2016: 13 · 2015: 11 · 2014: 17 · 2013: 20 · 2012: 9
FWCI
5.04
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (submittedVersion)
  • PubMed Central (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
nicotine withdrawal, smoking abstinence, nicotine dependence, striatum, cerebral cortex, urinary cotinine, carbon monoxide
MeSH terms
Adult, Animals, Azetidines, Cerebral Cortex

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-08.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-08.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review